Recently, the team led by Wu Zetao, a senior partner of ZhongYin, was engaged by several investors for representing them in a litigation against Jilin Province Ji'an Yisheng Pharmaceutical Co., Ltd. (stock short name Yisheng Pharmaceutical, stock code 002566) for misrepresentation involving securities.

On February 3, 2017, Yisheng Pharmaceutical was subject to administrative penalties by the CSRC for concealing its true shareholding structure and other violations related to information-disclosure during its listing. According to the Securities Law and relevant judicial interpretations, the investors who bought Yisheng Pharmaceutical stocks before the noon of December 28, 2015 and sell or hold Yisheng Pharmaceutical stocks after the noon of December 28, 2015 are entitled to claim compensation from Yisheng Pharmaceutical for their losses caused by its misrepresentation.

The team of Wu Zetao has extensive experience in practicing in capital markets and may deliver distinctive outcome in dispute resolution involving capital markets. As the presenting attorney for this case, the team will provide high-quality and efficient legal services to the investors in a diligent, responsible, professional and rigorous way.